Hemostatic Disorders in Hormonally Active Pituitary Tumors.
Endocrinopathies encompass heterogeneous diseases that can lead to hemostasis disorders at various stages over their clinical course. Normal hemostasis requires an equilibrium between the processes of coagulation and fibrinolysis, which depend on multiple activators and inhibitors. To date, the influence of various hormonal disorders on the hemostatic system has been assessed many times. The aim of this review was to analyze hemostasis abnormalities that occur in patients with hormonally active pituitary tumors: corticotropinoma, somatotropinoma, prolactinoma, gonadotropinoma and thyrotropinoma. Authors discuss studies that examined coagulation and hemostasis parameters among patients with these tumors, as well as analyze antithrombotic prophylaxis approach for endogenous hypercortisolemia subjects in particular.
Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Poland.
R
R
Świątkowska-Stodulska
Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Poland.
A
A
Babińska
Department of Hematology and Transplantology, Medical University of Gdańsk, Poland.
A
A
Mital
Department of Otolaryngology, Medical University of Gdańsk, Poland.
D
D
Stodulski
Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Poland.
K
K
Sworczak
D020141:Hemostatic Disorders / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D010911:Pituitary Neoplasms / Q000097:blood*